Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
The fair value price target for Alpha Cognition has shifted from about US$14.67 to US$16.75, which places the stock in a higher valuation range than before. Recent analyst commentary links this move to expectations around Zunveyl, including early launch progress, payer access, and the potential to address tolerability issues seen with existing Alzheimer's therapies. As you read on, you will see how these factors fit into the evolving Alpha Cognition story and how to track new information as it comes through.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Craig Hallum raised its Alpha Cognition price target to US$17 from US$14 after Q2 results that it described as strong, pointing to what it sees as improving commercial execution for Zunveyl.
-
The same firm highlighted active discussions with payers and a reported PA approval rate above 90%, which it views as supportive for near term estimates even before broader payer coverage.
-
Raymond James initiated Alpha Cognition with an Outperform rating and a US$20 price target, citing Zunveyl's design to address gastrointestinal tolerability issues with existing acetylcholinesterase inhibitors.
-
Maxim started coverage with a Buy rating and a US$12 price target and pointed to what it calls a significant market opportunity for Zunveyl in mild to moderate Alzheimer's dementia given high failure and switch rates with current options.
🐻 Bearish Takeaways
-
Despite positive tones from Craig Hallum, Raymond James, and Maxim, the coverage is still limited to a small group of firms, which can make it harder for you to benchmark Alpha Cognition against a broader set of third party views.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 1 risk for Alpha Cognition. See which could impact your investment.
How This Changes the Fair Value For Alpha Cognition
-
Fair Value for Alpha Cognition has moved from about US$14.67 to about US$16.75.
-
Revenue Growth has shifted from about 123.49% to about 99.39%.
-
Net Profit Margin has changed from about 19.89% to about 15.77%.
-
Future P/E has moved from about 19.51x to about 28.28x.
-
The Discount Rate has adjusted from about 7.14% to about 7.39%.
Never Miss an Update: Follow The Narrative
Narratives link Alpha Cognition's business story to a financial forecast and fair value so you can see how clinical, commercial and payer updates feed into the bigger picture. They refresh as new information comes through, which helps you keep context around each headline.
Head over to the Simply Wall St Community and follow the Narrative on Alpha Cognition to stay up to date on:
-
How ZUNVEYL uptake in long term care homes, repeat orders and higher dosing are shaping the core Alzheimer's franchise.
-
What growing payer engagement, post marketing Phase 4 work like RESOLVE and international plans through the CMS partnership could mean for future product reach.
-
Key risks around concentrated payer exposure, potential safety or tolerability issues, high operating expenses and execution risk in international and pricing plans.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ACOG .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
